Business
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of
About this update from Tenaya Therapeutics, Inc.
[{"type":"text","content":"Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy New Data Confirm TN-301’s Differentiated Mechanism and Opportunities to Positively Address Rare and Prevalent Cardiac, Metabolic and Muscular Conditions Tenaya Plans to Advance TN-301 Toward Phase 2 Clinical Development ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today presented encouraging preclinical data evaluating TN-301, the company’s highly selective HDAC6 inhibitor, at the Muscular Dystrophy Association’s Clinical & Scientific Conference 2026 (MDA 2026). In in vitro and in vivo models of Duchenne muscular dystrophy (DMD), TN-301 improved muscle performance and corrected key drivers of DMD cardiomyopathy. TN-301 is Tenaya’s potent and highly selective small molecule HDAC6 inhibitor with a multi-modal mechanism of action, including reducing inflammation, metabolic and mitochondrial dysregulation and fibrosis, and improving autophagy, which may have potential benefit in rare or prevalent cardiac, metabolic, muscle and pulmonary diseases. In a Phase 1 safety study in healthy adults, TN-301 was generally well tolerated over a wide dose range and did not demonstrate serious adverse events or dose-limiting toxicities. Based on this profile, Tenaya has identified several potential indications of interest, supported by the company’s previously published preclinical results in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy. Today’s presentation at MDA 2026 adds to this body of research, highlighting TN-301’s potential in DMD cardiomyopathy and muscle degeneration. Tenaya plans to advance TN-301 toward clinical studies in patients, with HFpEF and DMD being among the most promising potential indications identified to date. “DMD-related cardiomyopathy is the most common cause of death among individuals with DMD, and despite advances in care, there is a profound unmet need for treatments that can address both skeletal muscle atrophy and cardiac decline,” said Kathy Ivey, Ph.D...